FDA Approves the Zenflow Spring® Implant and Delivery System for First-Line Interventional Therapy of Patients with Benign Prostatic Hyperplasia (BPH)
Long-Term Data Supports Three-Year Durability
Innovative Design Allows for Only Tailored BPH Approach that Preserves Natural Anatomy
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) — Zenflow, Inc. announced today the U.S. Food and Drug Administration (FDA) approval of the Zenflow Spring® Implant and Delivery System for the treatment of symptoms associated with benign prostatic hyperplasia (BPH), also known as enlarged prostate. The Zenflow Spring Implant and Delivery System is a novel, first-line interventional therapy (FIT) that provides urologists and their patients with a minimally invasive option that has proven long-term durability and unique safety advantages, including no post-procedure catheterization and the ability to reverse treatment if desired.
